Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2004, Pages

  Antzelevitch, Charles ^a   Belardinelli, Luiz ^b   Wu, Lin ^b   Fraser, Heather ^b   Zygmunt, Andrew C ^a   Burashnikov, Alexander ^a   Di Diego, José M ^a   Fish, Jeffrey M ^a   Cordeiro, Jonathan M ^a   Goodrow Jr , Robert J ^a   Scornik, Fabiana ^a   Perez, Guillermo ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b CV THERAPEUTICS INC   (United States)

Author keywords

Anti ischemic; Antiarrhythmic; Early afterdepolarizations; IKr blocker; QT prolongation; Ranolazine; Transmural dispersion of repolarization

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALMOKALANT; AMIODARONE; ASTEMIZOLE; AZIMILIDE; BEPRIDIL; CISAPRIDE; DOFETILIDE; DROPERIDOL; ERYTHROMYCIN; IBUTILIDE; KETANSERIN; MIBEFRADIL; MOXIFLOXACIN; PENTOBARBITAL; PRENYLAMINE; QUINIDINE; RANOLAZINE; SERTINDOLE; SOTALOL; TERFENADINE; TERODILINE;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; DOG; DRUG POTENCY; ELECTROCARDIOGRAM; ELECTROSTIMULATION; ENANTIOMER; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ION CURRENT; NONHUMAN; PRIORITY JOURNAL; QT DISPERSION; QT PROLONGATION; REVIEW; T WAVE; TORSADE DES POINTES;

EID: 4944257316     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900106     Document Type: Review

References (146)

1. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 291:309-316, 2004
2. Louis AA, Manousos IR, Coletta AP, et al. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. Eur J Heart Fail 4:111-116, 2002
3. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 84:46-50, 1999
4. Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91:278-280, 2002
5. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiologic effects of ranolazine: A novel anti-anginal agent with antiarrhythmic properties. Circulation 110:904-910, 2004
6. Gintant GA, Limberis JT, McDermott JS, et al. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37:607-618, 2001
7. Wu L, Shryock JC, Song Y, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long QT syndrome. J Pharmacol Exp Ther 310:599-605, 2004
8. Okada Y, Ogawa S, Sadanaga T, et al. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol 27:84-89, 1996
9. Antzelevitch C, el Sherif N, Rosenbaum D, et al. Cellular mechanisms underlying the long QT syndrome. J Cardiovasc Electrophysiol 14:114-115, 2003
10. Belardinelli L, Antzelevitch C, Vos M. Potential predictors of drug-induced torsade de pointes: Early afterdepolarizations, ectopic beats and increased dispersion of ventricular repolarization. TIPS 24:619-625, 2003
11. CV Therapeutics. Ranexa (Ranolazine) FDA Review Documents. NDA 21-256, December 09, 2003
12. Malfatto G, Beria G, Sala S, et al. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol 23:296-301, 1994
13. Lupoglazoff JM, Denjoy I, Berthet M, et al. Notched T waves on Holter recordings enhance detection of patients with LQT2 (HERG) mutations. Circulation 103:1095-101, 2001
14. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation 98:1928-1936, 1998
15. Letienne R, Vie B, Puech A, et al. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol 363:464-471, 2001
16. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219-233, 2000
17. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17-26, 1964
18. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long-QT syndrome: Implications for patient care. Am Heart J 111: 1088-1093, 1986
19. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 2:806-817, 1983
20. Haverkamp W, Martinez-Rubio A, Hief C, et al. Efficacy and safety of d,1-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 30:487-495, 1997
21. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,1-sotalol. Circulation 94:2535-2541, 1996
22. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management. Am J Cardiol 80:82G-89G, 1997
23. Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Lancet 356:2052-2058, 2000
24. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94:1613-1621, 1996
25. Antzelevitch C. Heterogeneity of cellular repolarization in LQTS. The role of M cells. Eur Heart J Supplements 3:K-2-K-16, 2001
26. Antzelevitch C, Nesterenko VV, Muzikant AL, et al. Influence of transmural repolarization gradients on the electrophysiology and pharmacology of ventricular myocardium. Cellular basis for the Brugada and long-QT syndromes. Philos Trans R Soc Lond [Biol] 359:1201-216, 2001
27. Antzelevitch C, Shimizu W, Yan GX. Electrical heterogeneity and the development of arrhythmias. In Olsson SB, Yuan S, Amlie JP, eds: Dispersion of Ventricular Repolarization: State of the Art. Futura Publishing Company, Inc., New York, pp. 3-21, 2000
28. Antzelevitch C. Regional differences in electrophysiology of ventricular cells: Clinical implications for sudden cardiac death. In Aliot E, Clementy J, Prystowsky EN, eds: Fighting Sudden Cardiac Death: A Worldwide Challenge. Futura, Armonk, NY, pp. 109-130, 2000
29. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo. Torsade de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 11:290-304, 200
30. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell. Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 10:1124-1152, 1999
31. Antzelevitch C, Yan GX, Shimizu W, et al. Electrical heterogeneity, the ECG, and cardiac arrhythmias. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology: From Cell to Bedside. W.B. Saunders Co., Philadelphia, pp. 222-238, 1999
32. Anyukhovsky EP, Sosunov EA, Gainullin RZ, et al. The controversial M cell. J Cardiovasc Electrophysiol 10:244-260, 1999
33. Antzelevitch C, Dumaine R. Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications. In Page E, Fozzard HA, Solaro RJ, eds: Handbook of Physiology. The Heart. Oxford University Press, New York, pp. 654-692, 2001
34. Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle: The M cell. Circ Res 68:1729-1741, 1991
35. Antzelevitch C, Sicouri S, Litovsky SH, et al. Heterogeneity within the ventricular wall: Electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ Res 69:1427-1449, 1991
36. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiologic properties of epicardium, midmyocardium and endocardium: In vitro and in vivo correlations. Circulation 94:1981-1988, 1996
37. Ks contributes to the longer action potential of the M cell. Circ Res 76:351-365, 1995
38. Zygmunt AC, Eddlestone GT, Thomas GP, et al. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol 281:H689-H697, 2001
39. Na-Ca contributes to electrical heterogeneity within the canine ventricle. Am J Physiol 278:H1671-H1678, 2000
40. Sicouri S, Moro S, Litovsky SH, et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 8:1269-1279, 1997
41. Sun ZQ, Eddlestone GT, Antzelevitch C. Ionic mechanisms underlying the effects of sodium pentobarbital to diminish transmural dispersion of repolarization. [abstr]. PACE 20:11-16, 1997
42. Balser JR, Bennett PB, Hondeghem LM, et al. Suppression of time-dependent outward current in guinea-pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res 69:519-559, 1991
43. Shimizu W, McMahon B, Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsade de pointes in models of acquired and congenital long QT syndromes. J Cardiovasc Electrophysiol 10:156-164, 1999
44. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121:529-535, 1994
45. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT Syndrome. Circulation 104:2722-2727, 2001
46. Cui G, Sen L, Sager PT, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 74:896-900, 1994
47. + current by almokalant in rabbit ventricular myocytes. Circ Res 73:857-868, 1993
48. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsade de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. PACE 21:1044-1057, 1998
49. Carlsson L, Abrahamsson C, Andersson B, et al. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 27:2186-2193, 1993
50. Wiesfeld AC, Crijns HJ, Bergstrand RH, et al. Torsade de pointes with Almokalant, a new class III antiarrhythmic drug. Am Heart J 126:1008-1011, 1993
51. Abrahamsson C, Carlsson L, Duker G. Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early afterdepolarizations in vitro. J Cardiovasc Electrophysiol 7:1074-1081, 1996
52. Verduyn SC, Vos MA, Van der Zande J, et al. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: A comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol 30:1575-1584, 1997
53. Yang T, Snyders D, Roden DM. Drug block of I(kr): Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38:737-744, 2001
54. Kiehn J, Thomas D, Karle CA, et al. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359:212-219, 1999
55. Kodama I, Kamiya K, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84:20R-28R, 1999
56. Hii JTY, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes.Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 86:1376-1382, 1992
57. Merot J, Charpentier F, Poirier JM, et al. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol. Cardiovasc Res 44:303-314, 1999
58. Drouin E, Lande G, Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 32:1063-1067, 1998
59. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26:259-271, 1995
60. Busch AE, Eigenberger B, Jurkiewicz NK, et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: Mode of action. Br J Pharmacol 123:23-30, 1998
61. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-qt syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103:2851-2856,2001
62. van Opstal JM, Leunissen JD, Wellens HJ, et al. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of torsade de pointes arrhythmias. Eur J Pharmacol 412:67-76, 2001
63. Connolly SJ, Schnell DJ, Page RL, et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 88:974-979, 2001
64. Kiehn J, Lacerda AE, Wible BA, et al. Molecular physiology and pharmacology of HERG single-channel currents and block by dofetilide. Circulation 94:2572-2579, 1996
65. Kr. Implications for torsade de pointes and reverse use-dependence. Circulation 93:407-411, 1996
66. Lu HR, Remeysen P, De Clerck F. Nonselective 1(Kr)-blockers do not induce torsade de pointes in the anesthetized rabbit during alpha 1-adrenoceptor stimulation. J Cardiovasc Pharmacol 36:728-736, 2000
67. Buchanan LV, Kabell GG, Brunden MN, et al. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 22:540-549, 1993
68. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341:857-865, 1999
69. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 91:1799-1806, 1995
70. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 28:130-136, 1996
71. Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 103:253-257, 2001
72. Po SS, Wang DW, Yang IC, et al. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 33:181-185, 1999
73. Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J 107:425-430, 1984
74. Davidenko JM, Cohen L, Goodrow RJ, et al. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium. Circulation 79:674-686, 1989
75. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 56:857-867, 1985
76. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cell (M cells) in the canine heart: Quinidine and Digitalis. J Cardiovasc Electrophysiol 4:48-58, 1993
77. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther 232:817-825, 1985
78. Varro A, Balati B, Iost N, et al. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J Physiol (Lond) 523 Pt 1:67-81, 2000
79. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertin-dole in a rabbit heart model of torsade de pointes: Low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 300:64-71, 2002
80. McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 51:157-162, 1984
81. Patterson E, Scherlag BJ, Lazzara R. Early afterdepolarizations produced by d,1-sotalol and clofilium. J Cardiovasc Electrophysiol 8:667-678, 1997
82. Sicouri S, Moro S, Elizari MV. d-Sotalol induces marked action potential prolongation and early afterdepolarizations in M but not epicardial or endocardial cells of the canine ventricle. J Cardiovasc Pharmacol Ther 2:27-38, 1997
83. Suessbrich H, Waldegger S, Lang F, Bush AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizoles. FEBS Lett 385:77-80, 1996
84. Delpon E, Valenzuela C, Tamargo J. Blockade of cardiac potassium and other channels by antihistamines. Drug Saf 21 Suppl 1:11-18, 1999
85. Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electrophysiological actions of the histamine H-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76:110-119, 1995
86. Sakemi H, VanNatta B. Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J 125(5): 1436-1438, 1993
87. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 96:144-146, 1997
88. Weissenburger J, Noyer M, Cheymol G, Jaillon P. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Clin Exp Allergy 29 Suppl 3:190-196, 1999
89. Pratt CM, Hertz RP, Ellis BE, et al. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 73:346-352, 1994
90. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J 131:472-480, 1996
91. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsade de pointes occurring in association with terfenadine use. JAMA 264(21):2788-2790, 1990
92. Zimmermann M, Duruz H, Guinand O, et al. Torsade de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 13(7): 1002-1003, 1992
93. Daleau P, Lessard E, Groleau MF, et al. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91:3010-3016, 1995
94. Rampe D, Murawsky MK. Blockade of the human cardiac K+ channel Kv 1.5 by the antibiotic erythromycin. Naunyn Schmiedebergs Arch Pharmacol 355:743-750, 1997
95. Antzelevitch C, Sun ZQ, Zhang ZQ, et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT and torsade de pointes. J Am Coll Cardiol 28:1836-1348, 1996
96. Oberg KC, Bauman JL. QT interval prolongation and torsade de pointes due to erythromycin lactobionate. Pharmacotherapy 15:687-692, 1995
97. Gitler B, Berger LS, Buffa SD. Torsade de pointes induced by erythromycin. Chest 105:368-372, 1994
98. Fazekas T, Krassoi I, Lengyel C, et al. Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. PACE 21:147-150, 1998
99. Nattel S, Talajic M, Lemery R, Roy D. Erythromycin induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 89:235-238, 1990
100. Freedman RA, Anderson KP, Green LS, et al. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 59:168-169, 1987
101. Katapadi K, Kostandy G, Katapadi M, et al. A review of erythromycin-induced malignant tachyarrhythmia - torsade de pointes. A case report. Angiology 48:821-866, 1997
102. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175-187, 1999
103. Ohtani H, Taninaka C, Hanada E, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother 44:2630-2737, 2000
104. Wasmer K, Hindricks G, Kottkamp H. Clarithromycin-assoziierte synkope als erstmanifestation eines angeborenen langen QT-syndroms? Intensivmed 36:534-540, 1999
105. Lee KL, Jim MH, Tang SC, et al. QT prolongation and torsade de pointes associated with clarithromycin. Am J Med 104:395-396, 1998
106. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 303:218-225, 2002
107. Zhang S, Zhou Z, Gong Q, et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989-998, 1999
108. Hollifield JW, Heusner JJ, DesChamps M, et al. Comparison of equal-weight oral dosages of verapamil hydrochloride and diltiazem hydrochloride in patients with mild to moderate hypertension. Clin Pharm 7:129-134, 1988
109. Singh BN. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group. Am J Cardiol 68:306-312, 1991
110. Chouabe C, Drici MD, Romey G, et al. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie 55:195-202, 2000
111. De Cicco M, Macor F, Robieux I, et al. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: Clinical experience in the intensive care unit. Crit Care Med 27:332-339, 1999
112. Benardeau A, Weissenburger J, Hondeghem L, et al. Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue. J Pharmacol Exp Ther 292:561-575, 2000
113. Gonzalez-Gomez A, Cires PM, Gamio CF, et al. Relationships between verapamil plasma concentrations and its antihypertensive action. Int J Clin Pharmacol Ther Toxicol 26:453-460, 1988
114. Boutarin J, Maarek-Charbit M, Aupetit JF, et al. [Efficacy and tolerability of isoptine LP in mild to moderate hypertension. A multicenter study with 50 patients]. Ann Cardiol Angeiol (Paris) 41:587-593, 1992
115. Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. J Pharmacol Exp Ther 276:637-646, 1996
116. Glaser S, Steinbach M, Opitz C, et al. Torsade de pointes caused by Mibefradil. Eur J Heart Fail 3:627-630, 2001
117. Pinto JM, Sosunov EA, Gainullin RZ. Effects of mibefradil, a T-type calcium current antagonist, on electrophysiology of Purkinje fibers that survived in the infarcted canine heart. J Cardiovasc Electrophysiol 10:1224-1235, 1999
118. Rowland E, McKenna WJ, Krikler DM. Electrophysiologic and antiarrhythmic actions of bepridil. Comparison with verapamil and ajmaline for atrioventricular reentrant tachycardia. Am J Cardiol 55:1513-1519, 1985
119. Manouvrier J, Sagot M, Caron C, et al. Nine cases of torsade de pointes with bepridil administration. Am Heart J 111:1005-1007, 1986
120. Osaka T, Kodama I. Toyama J, et al. Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties. Br J Pharmacol 93:775-780, 1988
121. Prystowsky EN. Electrophysiologic and antiarrhythmic properties of bepridil. Am J Cardiol 55:59C-62C, 1985
122. Campbell RM, Woosley RL, Iansmith DH, et al. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. PACE 13:30-36, 1990
123. Rampe D, Murawsky MK, Grau J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286:788-793, 1998
124. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124:168-175, 1996
125. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782-791, 1997
126. Fritze J, Bandelow B. The QT interval and the atypical antipsychotic sertindole. Int J Psych Clinc Pract 2:265-273, 1998
127. Thomsen MB, Volders PGA, Spatjens RL, et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. [abstr]. PACE 26 (Pt 2): 1089, 2003
128. Drolet B, Zhang S, Deschenes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 10:1597-1604, 1999
129. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 79:983-986, 1994
130. Guy JM, Andre-Fouet X, Porte J, et al. [Torsade de pointes and prolongation of the duration of QT interval after injection of droperidol]. Ann Cardiol Angeiol (Paris) 40:541-545, 1991
131. Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32:761-765, 1998
132. Adamantidis MM, Kerram P, Caron JF, et al. Droperidol exerts dual effects on repolarization and induces early afterdepolarizations and triggered activity in rabbit Purkinje fibers. J Pharmacol Exp Ther 266:884-893, 1993
133. Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273:H2534-H2538, 1997
134. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97:204-210, 1998
135. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 335:290-291, 1996
136. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108:1027-1033, 2003
137. Chen YJ, Lee SH, Hsieh MH, et al. Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. J Cardiovasc Electrophysiol 10:587-598, 1999
138. Puisieux FL, Adamantidis MM, Dumotier BM, et al. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 117:1377-1379, 1996
139. Le Grand B, Talmant JM, Rieu JP, et al. Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential. J Cardiovasc Pharmacol 26:803-809, 1995
140. Aldariz AE, Romero H, Baroni M, et al. QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin. PACE 9:836-841, 1986
141. Zaza A, Malfatto G, Rosen MR. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. J Pharmacol Exp Ther 250:397-405, 1989
142. na block produces a relatively homogeneous prolongation of repolarization of cells spanning the canine left ventricular wall. [abstr]. PACE 20:II-1216, 1997
143. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 35:778-786, 2000
144. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 10:1124-1152, 1999
145. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96:2038-2047, 1997
146. Shimizu W, Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 102: 706-712, 2000